CIK细胞治疗90例肿瘤患者的安全性分析  

An Analysis of the Safety in CIK Treatment for 90 Cases with Cancer

作　　者：马学斌[1] 马聪[1] 邱伟[1] 袁红霞[1] 杨平[1] 王小会[1] 康静波[1] 

机构地区：[1]海军总医院,北京100048

出　　处：《肿瘤学杂志》2014年第3期230-233,共4页Journal of Chinese Oncology

摘　　要：[目的]探讨细胞因子诱导的杀伤细胞(CIK)治疗肿瘤患者的安全性。[方法]回顾性分析90例接受CIK细胞治疗的肿瘤患者的临床资料。[结果]90例接受CIK细胞治疗的患者中,病情均出现不同程度的好转。不良反应中发热者14例,发生率为15.5%;出现咽痛咳嗽者2例,乏力加重和肌肉酸痛2例,输注后肿瘤部位疼痛剧烈1例,胸闷1例,未发现有明显的肝肾功能异常和心电图异常。治疗前后患者血常规和肝肾功结果无显著性差异,无治疗相关性死亡。[结论]CIK细胞治疗是安全有效的,相关不良反应可对症处理。[Purpose] To investigate the safety in cytokine-induced killer cells（CIK） treatment for cancer patients. [Methods] The clinical data of 90 cancer patients receiving CIK treatment were analyzed retrospectively. [Results] All the 90 patients’ condition were improved with varying degree after CIK treatment. The main toxicities after infusion were fever（15 cases,15.5%）,cough and throat ache（2 cases）,increasing fatigue and muscle ache（2 cases）,acute pain in tumor location（1 case）,chest distress（1 case）,and there was no obviously liver or renal dysfunction or abnormal ECG. There was no significant difference in liver function or renal function or blood routine examination before and after treatment,and there was no death related to CIK treatment. [Conclusion] CIK treatment is safety and effective for patients with malignancy and its toxicities may be treated expectantly.

关 键 词：细胞因子诱导的杀伤细胞 安全性 不良反应 

分 类 号：R730.54[医药卫生—肿瘤]